Search the Newsreel

Glaukos Number of Employees 2026 | Employee Count & Headcount Data

Glaukos Corp. (GKOS) has grown its total workforce to 1,138 employees worldwide as of March 2026, marking a 24.2% increase from 2023. The company is actively hiring with 89 job postings in 2026 and its workforce is primarily concentrated in the United States, with …

Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

Glaukos Raises 2026 Sales Guidance to $680M-$700M Range

Glaukos (NYSE:GKOS) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Glaukos Corp (GKOS) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Glaukos Corp (GKOS), noting its current risk assessment score of 5.96 and its ranking within the Healthcare Equipment & Supplies industry. It details various risk metrics including the company's beta value of 0.86, suggesting lower volatility compared …

Glaukos: A Further Guidance Hike On Revenues Could Spike Shares Post Q2 Release (GKOS)

Glaukos (GKOS) shares are approaching technical resistance near $160 ahead of its Q2 earnings release, maintaining a "Hold" rating. Strong revenue growth, with a 91% stock rally since last year, is driven by Q1's 41%+ and Q3's 38% YoY growth. Key factors for a …

Stifel reiterates Glaukos stock rating on Epioxa demand strength

Stifel maintained a Buy rating and a $175 price target for Glaukos Corporation (NYSE:GKOS) due to the strong intermediate-to-long-term prospects of its Epioxa drug, supported by robust early demand identified through ophthalmologist surveys. The firm projects significant market growth and peak sales of $1.5 …

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt

Glaukos Corporation announced the completion of patient enrollment in its U.S. 510(k) pivotal study for the PRESERFLO™ MicroShunt. This device is designed to treat primary open-angle glaucoma in patients who have not responded to previous medical and surgical treatments. The company aims to use …

Glaukos completes enrollment in pivotal trial of PRESERFLO MicroShunt for treatment-resistant glaucoma

Glaukos Corporation has successfully completed patient enrollment for its US pivotal study of the PRESERFLO MicroShunt, a device designed to treat advanced glaucoma in patients who have not responded to prior incisional or cilioablative surgeries. The trial included over 110 patients across the US …

Glaukos Corp Revenue Breakdown – BX:GKOS

Glaukos Corporation (BX:GKOS) generated 402.28 million CHF last year, with its Glaucoma segment being the top performer, contributing 333.81 million CHF. The United States was the largest geographical contributor, accounting for 297.32 million CHF of the company's revenue. This financial data highlights the company's …

Glaukos completes enrollment with at least 110 glaucoma patients

Glaukos Corporation announced the completion of patient enrollment in its U.S. 510(k) pivotal study for the PRESERFLO MicroShunt, a device designed to lower intraocular pressure in patients with primary open-angle glaucoma who had previous unsuccessful treatments. The study enrolled at least 110 patients and …

How PRESERFLO Trial Enrollment Completion Could Shape Glaukos’ (GKOS) Long-Term Glaucoma Pipeline Strategy

Glaukos recently completed patient enrollment for its PRESERFLO MicroShunt trial, moving the device closer to potential FDA submission. This milestone, along with the recent iDose TR labeling update, helps diversify Glaukos' long-term glaucoma pipeline. However, the company still faces challenges with profitability, R&D costs, …

Glaukos Corp - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on treatments for glaucoma, corneal disorders, and retinal diseases, with its Glaucoma business being the largest revenue generator. The article provides a detailed company profile, including financial data, market performance, executive information, and …

Glaukos Corp (GKOS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Glaukos Corp (GKOS) has an earnings forecast score of 8.50, ranking 26th in its industry, with an average price target of $120.00 from analysts. The consensus among 15 analysts is a "Buy" rating for GKOS. The company's expected revenue for the next quarter is …

Glaukos Corp (GKOS) Financial Health: Profitability & Balance Sheet Analysis

TradingKey has assessed Glaukos Corp (GKOS), assigning it a financial score of 7.96, which ranks it 50th out of 200 in the Healthcare Equipment & Supplies industry, indicating robust financial health and high operating efficiency. The company reported a 41.16% year-over-year increase in its …

Earnings Preview: Glaukos to Report Financial Results Post-market on July 29

Glaukos Corporation is set to report its financial results after the market closes on July 29. Investors will be looking for key metrics such as earnings per share and revenue to assess the company's performance. The upcoming earnings call will provide further details and …

Glaukos (GKOS) Projected to Announce Earnings on Wednesday

Glaukos Corp (NYSE: GKOS) CFO trades 10,000 shares under Rule 10b5-1 plan

Glaukos Corp's CFO, Alex R. Thurman, exercised options for 10,000 shares at $38.68 each and then sold all 10,000 shares at $160.00 each on July 16, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025. Following …

Glaukos (GKOS) Q1 2026 earnings summary

Glaukos (GKOS) reported record Q1 2026 net sales of $150.6 million, a 41% year-over-year increase, driven by strong performance in glaucoma and corneal health, particularly with iDose TR. The company raised its full-year 2026 net sales guidance to $620M–$635M, reflecting confidence in its key …

Glaukos Corporation (GKOS) Stock Analysis: Robust Revenue Growth and Strong Buy Ratings Signal Positive Investor Outlook

Glaukos Corporation (GKOS) shows strong investor confidence with robust revenue growth of 41.20% and 13 unanimous buy ratings from analysts, despite negative EPS and ROE indicating heavy reinvestment. The company, known for ophthalmic treatments like iStent and iDose TR, trades above its moving averages …

How Glaukos Corporation (GKOS) Affects Rotational Strategy Timing

This article from Stock Traders Daily analyzes Glaukos Corporation (GKOS) through AI models, indicating a strong overweight bias across all time horizons. It provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis to guide investors.

Stifel raises Glaukos stock price target to $175 on iDose outlook By Investing.com

Stifel increased its price target for Glaukos Corporation to $175 from $170, maintaining a Buy rating based on the positive outlook for its iDose product. Despite the stock appearing overvalued by some metrics, Stifel's analysis anticipates strong iDose sales, especially with increased doctor expectations …

GLAUKOS CORP : TRUIST SECURITIES RAISES TARGET PRICE TO $180 FROM $160

Truist Securities has increased its target price for Glaukos Corp (GKOS.N) shares from $160 to $180. The content of this article reflects the author's opinion and is not intended as investment advice. Investors are encouraged to understand the market before making trading decisions.

GKOS Maintained by Truist Securities -- Price Target Raised to $180

Truist Securities maintained a 'Buy' rating for Glaukos (GKOS) and increased its price target from $160 to $180, reflecting confidence in the company's growth potential in ophthalmic medical technologies. Although the stock is considered strong in growth and momentum with a GF Score™ of …

Alex R. Thurman to sell 10,000 Glaukos (GKOS) shares under Form 144

Alex R. Thurman, a shareholder of Glaukos (GKOS), has filed a Form 144 notice to sell 10,000 shares of common stock on the NYSE through Fidelity Brokerage, valued at $1,600,000. These shares were acquired via a cash stock option exercise on July 16, 2026. …

Glaukos sets July 29 call for Q2 results after market close

Earnings Update: Here's Why Analysts Just Lifted Their Glaukos Corporation (NYSE:GKOS) Price Target To US$148

Glaukos (GKOS) Q1 Loss Of US$0.34 EPS Reinforces Bearish Profitability Narrative

Glaukos (GKOS) Jumps As Earnings Beat Fuels Bullish Outlook

Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook

GKOS Stock Jumps As Earnings Beat And Guidance Lift Fuel Momentum

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos sets April 29 earnings release, webcast after market close

Why Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report?

Glaukos Stock Jumps 13% After Q4 Beat: Here’s What Its 2026 Guidance Signals